Asenapine: Efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder
Authors:
- 1 January 2016
- journal article
- research article
- Published by Elsevier in Journal of Affective Disorders
- Vol. 190, 103-110
Abstract
No abstract availableKeywords
Funding Information
- Forest Laboratories, LLC, an Allergan affiliate.
This publication has 18 references indexed in Scilit:
- Asenapine for long-term treatment of bipolar disorder: A double-blind 40-week extension studyJournal of Affective Disorders, 2010
- Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trialJournal of Affective Disorders, 2010
- Asenapine versus olanzapine in acute mania: a double‐blind extension studyBipolar Disorders, 2009
- A 3‐week, randomized, placebo‐controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed statesBipolar Disorders, 2009
- A graphical approach to sequentially rejective multiple test proceduresStatistics in Medicine, 2008
- Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- DSM-IH-R Psychotic Disorders: procedural validity of the Mini International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDIEuropean Psychiatry, 1998
- A Rating Scale for Drug-Induced AkathisiaThe British Journal of Psychiatry, 1989
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987